Cattaneo, Carlo http://orcid.org/0009-0006-7810-4514
Kulisevsky, Jaime http://orcid.org/0000-0003-4870-1431
Clinical trials referenced in this document:
Documents that mention this clinical trial
The Effects of Safinamide in Chinese and Non-Chinese Patients with Parkinson’s Disease
https://doi.org/10.1007/s12325-023-02736-2
Documents that mention this clinical trial
The Effects of Safinamide in Chinese and Non-Chinese Patients with Parkinson’s Disease
https://doi.org/10.1007/s12325-023-02736-2
Long-acting exenatide does not prevent cognitive decline in mild cognitive impairment: a proof-of-concept clinical trial
https://doi.org/10.1007/s40618-024-02320-7
Funding for this research was provided by:
Zambon
Article History
Received: 2 October 2023
Accepted: 9 November 2023
First Online: 9 December 2023
Declarations
:
: Carlo Cattaneo is an employee of Zambon SpA; Jaime Kulisevsky has received compensation for consultancy and speaker related activities from Zambon SpA.
: This article is based on the data of the previously conducted studies SUCCESS and XINDI that have been approved in all countries by ethical national committees and national health authorities and were performed according to the guidelines of the Declaration of Helsinki. The authors received permission to access the data. No new studies with human participants have been performed for this publication. Written informed and privacy consents to participate in the studies SUCCESS and XINDI, collect, analyze, and report anonymized and aggregated data were obtained from all patients.